Macronutrients and obesity: Views, news and reviews

Future Lipidology

Volumn 3, Issue 1, 2008, Pages 43-74

  Madsen, Lise ^a,b,c   Liaset, Bjørn ^b   Kristiansen, Karsten ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b INSTITUTE OF MARINE RESEARCH   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Adipocyte differentiation; Carbohydrate; Diet; Fat; Gut hormones; Macronutrients; Obesity; Polyunsaturated fatty acids; Protein

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BEZAFIBRATE; BRANCHED CHAIN AMINO ACID; CATECHOLAMINE DERIVATIVE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ B RECEPTOR; DOCOSAHEXAENOIC ACID; FENOFIBRATE; FISH OIL; GHRELIN; GLUCAGON; GLUCOSE; INCRETIN; INSULIN; LINOLEIC ACID; LIVER X RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEPTIDE YY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRACE ELEMENT; TRANSCRIPTION FACTOR; TYROSINE; UNINDEXED DRUG; UNSATURATED FATTY ACID;

ADIPOCYTE; CARBOHYDRATE INTAKE; CELL DIFFERENTIATION; CELL FUNCTION; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; EATING HABIT; ENERGY BALANCE; FAT INTAKE; FATTY ACID OXIDATION; FOOD COMPOSITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; LIPOGENESIS; LIPOLYSIS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTAKE; REVIEW; SATIETY; TRANSCRIPTION REGULATION;

EID: 40749109271     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.1.43     Document Type: Review

References (436)

1. Prentice AM: Fires of life: the struggles of an ancient metabolism in a modern World. Nutrition Bulletin 26(1), 13-27 (2001).
2. Neel J: Diabetes mellitus: a 'thrifty' genotype rendered detrimental by "progress". Am. J. Hum. Genet. 14, 353-362 (1962).
3. Paradies YC, Montoya MJ, Fullerton SM: Racialized genetics and the study of complex diseases: the thrifty genotype revisited. Perspect. Biol. Med. 50(2), 203-227 (2007).
4. Speakman JR: A nonadaptive scenario explaining the genetic predisposition to obesity: the "predation release" hypothesis. Cell Metab. 6(1), 5-12 (2007).
5. Watve M, Yajnik C: Evolutionary origins of insulin resistance: a behavioral switch hypothesis. BMC Evol. Biol. 7(1), 61 (2007).
6. Cordain L, Eaton SB, Sebastian A et al.: Origins and evolution of the Western diet: health implications for the 21st Century. Am. J. Clin. Nutr. 81(2), 341-354 (2005).
7. Eaton S, Eaton SB, Konner MJ et al.: An evolutionary perspective enhances understanding of human nutritional requirements. J. Nutr. 126(6), 1732-1740 (1996).
8. Cordain L, Miller JB, Eaton SB et al.: Plant-animal subsistence ratios and macronutrient energy estimations in worldwide hunter-gatherer diets. Am. J. Clin. Nutr. 71(3), 682-692 (2000).
9. Eaton SB: The ancestral human diet: what was it and should it be a paradigm for contemporary nutrition? Proc. Nutr. Soc. 65(1), 1-6 (2006).
10. Gaulin S, Konner M: On the natural diet of primates, including humans. In: Nutrition and the Brain (Vol. 1). Wurtman RJ, Wurtman JJ (Eds). New York Raven Press, NY, USA 1-86 (1977).
11. Brand-Miller JC, Holt SH: Australian aboriginal plant foods: a consideration of their nutritional composition and health implications. Nutr. Res. Rev. 11, 5-23 (1998).
12. Cordain L, Eaton SB, Miller JB et al.: The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic. Eur. J. Clin. Nutr. 56(S1), S42-S52 (2002).
13. Connor WE, Connor SL, Katan MB et al.: Should a low-fat, high-carbohydrate diet be recommended for everyone? N. Engl. J. Med. 337(8), 562-567 (1997).
14. Hill JO, Wyatt HR, Reed GW et al.: Obesity and the environment: where do we go from here? Science 299(5608), 853-855 (2003).
15. Weinberg SL: The diet-heart hypothesis: a critique. J. Am. Coll. Cardiol. 43(5), 731-733 (2004).
16. Eaton SB, Eaton SB 3rd: Paleolithic vs. modern diets - selected pathophysiological implications. Eur. J. Nutr. 39(2), 67-70 (2000).
17. Crawford M: Fatty acids in free-living and domestic animals. Lancet 291(7556), 1329-1333 (1968).
18. Ailhaud G, Massiera F, Weill P et al.: Temporal changes in dietary fats: role of n-6 polyunsaturated fatty acids in excessive adipose tissue development and relationship to obesity. Prog. Lipid Res. 45(3), 203-236 (2006).
19. Cleary M, Phillips F, Morton R: Genotype and diet effects in lean and obese Zucker rats fed either safflower or coconut oil diets. Proc. Soc. Exp. Biol. Med. 220(3), 153-161 (1999).
20. Massiera F, Saint-Marc P, Seydoux J et al.: Arachidonic acid and prostacyclin signaling promote adipose tissue development: a human health concern? J. Lipid Res. 44(2), 271-279 (2003).
21. Prentice AM: Overeating: the health risks. Obes. Res. 9(90004), 234S-238S (2001).
22. Matsuo T, Takeuchi H, Suzuki H et al.: Body fat accumulation is greater in rats fed a beef tallow diet than in rats fed a safflower or soybean oil diet. Asia Pac. J. Clin. Nutr. 11(4), 302-308 (2002).
23. Okuno M, Kajiwara K, Imai S et al.: Perilla oil prevents the excessive growth of visceral adipose tissue in rats by down-regulating adipocyte differentiation. J. Nutr. 127(9), 1752-1757 (1997).
24. Belzung F, Raciot T, Groscolas R: Fish oil n-3 fatty acids selectively limit the hypertrophy of abdominal fat depots in growing rats fed high-fat diets. Am. J. Physiol. 246(6 Pt 2), R1111-R1118 (1993).
25. Hill JO, Peters JC, Lin D et al.: Lipid accumulation and body fat distribution is influenced by type of dietary fat fed to rats. Int. J. Obes. Relat. Metab. Diord. 17(4), 223-236 (1993).
26. Parrish CC, Pathy DA, Angel A: Dietary fish oils limit adipose tissue hypertrophy in rats. Metabolism 39(3), 217-219 (1990).
27. Raclot T, Groscolas R, Langin D et al.: Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J. Lipid Res. 38(10), 1963-1972 (1997).
28. Rustan AC, Hustvedt BE, Drevon CA: Dietary supplementation of very long-chain n-3 fatty acids decreases whole body lipid utilization in the rat. J. Lipid Res. 34(8), 1299-1309 (1993).
29. Ukropec J, Reseland JE, Gasperikova D et al.: The hypotriglyceridemic effect of dietary n-3 FA is associated with increased β-oxidation and reduced leptin expression. Lipids 38(10), 1023-1029 (2003).
30. van de Vijver LP, Kardinaal AF, Couet C et al.: Association between trans fatty acid intake and cardiovascular risk factors in Europe: the TRANSFAIR study. Eur. J. Clin. Nutr. 54(2), 126-135 (2000).
31. Stender S, Dyerberg J, Bysted A et al.: A trans world journey. Atheroscler. Suppl. 7(2), 47-52 (2006).
32. Stender S, Dyerberg J, Astrup A: High levels of industrially produced trans fat in popular fast foods. N. Engl. J. Med. 354(15), 1650-1652 (2006).
33. Enig MG, Atal S, Keeney M et al.: Isomeric trans fatty acids in the U.S. diet. J. Am. Coll. Nutr. 9(5), 471-486 (1990).
34. Sun Q, Ma J, Campos H et al.: A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 115(14), 1858-1865 (2007).
35. Kavanagh K, Jones KL, Sawyer J et al.: Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity Res. 15(7), 1675-1684 (2007).
36. Borlotto J, Reis C, Ferreira A et al.: Higher content of trans fatty acids in abdominal visceral fat of morbidly obese individuals undergoing bariatric surgery compared to non-obese subjects. Obes. Surg. 15(9), 1265-1270 (2005).
37. Park Y, Storkson JM, Albright KJ et al.: Evidence that the trans-10, cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 34, 235-241 (1999).
38. Ryder JW, Portocarrero CP, Song XM et al.: Isomer-specific antidiabetic properties of conjugated linoleic acid: improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 50(5), 1149-1157 (2001).
39. Sisk MB, Hausman DB, Martin RJ et al.: Dietary conjugated linoleic acid reduces adiposity in lean but not obese Zucker rats. J. Nutr. 131(6), 1668-1674 (2001).
40. Terpstra AHM, Beynen AC, Everts H et al.: The decrease in body fat in mice fed conjugated linoleic acid is due to increases in energy expenditure and energy loss in the excreta. J. Nutr. 132(5), 940-945 (2002).
41. West DB, Delany JP, Camet PM et al.: Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am. J. Physiol. 275, R667-R672 (1998).
42. Whigham LD, Watras AC, Schoeller DA: Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am. J. Clin. Nutr. 85(5), 1203-1211 (2007).
43. Riserus U: Trans fatty acids and insulin resistance. Atheroscler. Suppl. 7(2), 37-39 (2006).
44. Gaesser GA: Carbohydrate quantity and quality in relation to body mass index. J. Am. Diet Assoc. 107(10), 1768-1780 (2007).
45. Englyst KN, Englyst HN: Carbohydrate bioavailability. Br. J. Nutr. 94(1), 1-11 (2005).
46. Eaton SB: Fibre intake in prehistoric times. In: Dietary Fibre Perspectives (Vol. 2). Libby J 2nd (Ed.). Reviews and Bibliography, London, UK 27-40 (1990).
47. Ylonen K, Saloranta C, Kronberg-Kippila C et al.: Associations of dietary fiber with glucose metabolism in nondiabetic relatives of subjects with Type 2 diabetes: the Botnia dietary study. Diabetes Care 26(7), 1979-1985 (2003).
48. McIntosh M, Miller C: A diet containing food rich in soluble and insoluble fiber improves glycemic control and reduces hyperlipidemia among patients with Type 2 diabetes mellitus. Nutr. Rev. 59(2), 52-55 (2001).
49. Liese AD, Schulz M, Fang F et al.: Dietary glycemic index and glycemic load, carbohydrate and fiber intake, and measures of insulin sensitivity, secretion, and adiposity in the Insulin Resistance Atherosclerosis Study. Diabetes Care 28(12), 2832-2838 (2005).
50. Brand JC, Nicholson PL, Thorburn AW et al.: Food processing and the glycemic index. Am. J. Clin. Nutr. 42(6), 1192-1196 (1985).
51. Hawkins A, Johnson SK: In vitro carbohydrate digestibility of whole-chickpea and chickpea bread products. Int. J. Food Sci. Nutr. 56(3), 147-155 (2005).
52. Ross SW, Brand JC, Thorburn AW et al.: Glycemic index of processed wheat products. Am. J. Clin. Nutr. 46(4), 631-635 (1987).
53. Brand JC, Snow BJ, Nabhan GP et al.: Plasma glucose and insulin responses to traditional Pima Indian meals. Am. J. Clin. Nutr. 51(3), 416-420 (1990).
54. Thorburn AW, Brand JC, Truswell AS: Slowly digested and absorbed carbohydrate in traditional bushfoods: a protective factor against diabetes? Am. J. Clin. Nutr. 45(1), 98-106 (1987).
55. Pawlak DB, Kushner JA, Ludwig DS: Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet 364 (9436), 778-785 (2004).
56. Jeon BS, Park JW, Kim BK et al.: Fermented mushroom milk-supplemented dietary fibre prevents the onset of obesity and hypertriglyceridaemia in Otsuka Long-Evans Tokushima fatty rats. Diabetes Obes. Metab. 7(6), 709-715 (2005).
57. Cleave TL. In: The Saccharine Disease. John Wright & Sons Ltd, Bristol, UK 6-27 (1974).
58. Parks EJ, Parks EJ: Changes in fat synthesis influenced by dietary macronutrient content. Proc. Nutr. Soc. 61(2), 281-286 (2002).
59. Sugden MC: In appreciation of Sir Philip Randle: the glucose-fatty acid cycle. Br. J. Nutr. 97(5), 809-813 (2007).
60. Morral N, Edenberg HJ, Witting SR et al.: Effects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liver. J. Lipid Res. 48(7), 1499-1510 (2007).
61. Chong MF, Fielding BA, Frayn KN: Metabolic interaction of dietary sugars and plasma lipids with a focus on mechanisms and de novo lipogenesis. Proc. Nutr. Soc. 66(1), 52-59 (2007).
62. Hudgins LC, Baday A, Hellerstein MK et al.: The effect of dietary carbohydrate on genes for fatty acid synthase and inflammatory cytokines in adipose tissues from lean and obese subjects. J. Nutr. Biochem. (2007) (Epub ahead of print).
63. Hudgins LC, Hellerstein MK, Seidman CE et al.: Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J. Lipid Res. 41(4), 595-604 (2000).
64. Forshee RA, Storey ML, Allison DB et al.: A critical examination of the evidence relating high fructose corn syrup and weight gain. Crit. Rev. Food Sci. Nutr. 47(6), 561-582 (2007).
65. Curry DL: Effects of mannose and fructose on the synthesis and secretion of insulin. Pancreas 4(1), 2-9 (1989).
66. Teff KL, Elliott SS, Tschop M et al.: Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J. Clin. Endocrinol. Metab. 89(6), 2963-2972 (2004).
67. Jurgens H, Haass W, Castaneda TR et al.: Consuming fructose-sweetened beverages increases body adiposity in mice. Obesity Res. 13(7), 1146-1156 (2005).
68. Kasim-Karakas SE, Vriend H, Almario R et al.: Effects of dietary carbohydrates on glucose and lipid metabolism in golden Syrian hamsters. J. Lab. Clin. Med. 128(2), 208-213 (1996).
69. Bell RC, Ryan EA, Finegood DT: Consequences of high dietary fructose in the islet-transplanted rat with suboptimal β-cell mass. Am. J. Physiol. Endocrinol. Metab. 270(2), E292-E298 (1996).
70. Luo Y, Tall AR: Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Investig. 105, 513-520 (2000).
71. Thorburn AW, Storlien LH, Jenkins AB et al.: Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am. J. Clin. Nutr. 49(6), 1155-1163 (1989).
72. Zavaroni I, Sander S, Scott S et al.: Effect of fructose feeding on insulin secretion and insulin action in the rat. Metabolism 29(10), 970-973 (1980).
73. Martinez FJ, Rizza RA, Romero JC: High-fructose feeding elicits insulin resistance, hyperinsulinism, and hypertension in normal mongrel dogs. Hypertension 23(4), 456-463 (1994).
74. Faeh D, Minehira K, Schwarz JM et al.: Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 54(7), 1907-1913 (2005).
75. Le KA, Faeh D, Stettler R et al.: A 4-wk high-fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am. J. Clin. Nutr. 84(6), 1374-1379 (2006).
76. Rayssiguier Y, Gueux E, Nowacki W et al.: High fructose consumption combined with low dietary magnesium intake may increase the incidence of the metabolic syndrome by inducing inflammation. Magnes. Res. 19(4), 237-243 (2006).
77. Rutledge AC, Adeli K: Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutr. Rev. 65(6 Pt 2), S13-S23 (2007).
78. Garlick PJ: The role of leucine in the regulation of protein metabolism. J. Nutr. 135(6), 1553S-1556S (2005).
79. Fernstrom MH, Fernstrom JD: Brain tryptophan concentrations and serotonin synthesis remain responsive to food consumption after the ingestion of sequential meals. Am. J. Clin. Nutr. 61(2), 312-319 (1995).
80. Institute of Medicine (IOM) of the National Academies. Dietary Reference Intakes for Energy, Carbohydrate, Fibre, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. The National Academies Press, Washington DC, USA (2002).
81. Nordic Council of Ministers. Nordic Nutrition Recommendation 2004: Integrating Nutrition and Physical Activity. Scanprint, Copenhagen, Denmark (2004).
82. Bernstein AM, Treyzon L, Li Z: Are high-protein, vegetable-based diets safe for kidney function? A review of the literature. J. Am. Diet Assoc. 107(4), 644-650 (2007).
83. Murtaugh MA, Herrick JS, Sweeney C et al.: Diet composition and risk of overweight and obesity in women living in the southwestern United States. J. Am. Diet Assoc. 107(8), 1311-1321 (2007).
84. Farnsworth E, Luscombe ND, Noakes M et al.: Effect of a high-protein, energy-restricted diet on body composition, glycemic control, and lipid concentrations in overweight and obese hyperinsulinemic men and women. Am. J. Clin. Nutr. 78(1), 31-39 (2003).
85. Leidy HJ, Mattes RD, Campbell WW: Effects of acute and chronic protein intake on metabolism, appetite, and ghrelin during weight loss. Obesity Res. 15(5), 1215-1225 (2007).
86. Lowell BB, Spiegelman BM: Towards a molecular understanding of adaptive thermogenesis. Nature 404(6778), 652-660 (2000).
87. Sims EA, Danforth EJ: Expenditure and storage of energy in man. J. Clin. Invest. 79(4), 1019-1025 (1987).
88. Shibata H, Bukowiecki LJ: Regulatory alterations of daily energy expenditure induced by fasting or overfeeding in unrestrained rats. J. Appl. Physiol. 63(2), 465-470 (1987).
89. Fine EJ, Feinman RD: Thermodynamics of weight loss diets. Nutr. Metab. 1(1), 15-23 (2004).
90. Johnston CS, Day CS, Swan PD: Postprandial thermogenesis is increased 100% on a high-protein, low-fat diet versus a high-carbohydrate, low-fat diet in healthy, young women. J. Am. Coll. Nutr. 21(1), 55-61 (2002).
91. Mikkelsen PB, Toubro S, Astrup A: Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein, vegetable protein, and carbohydrate. Am. J. Clin. Nutr. 72(5), 1135-1141 (2000).
92. Robinson SM, Jaccard C, Persaud C et al.: Protein turnover and thermogenesis in response to high-protein and high- carbohydrate feeding in men. Am. J. Clin. Nutr. 52(1), 72-80 (1990).
93. Foster GD, Wyatt HR, Hill JO et al.: A randomized trial of a low-carbohydrate diet for obesity. N. Engl. J. Med. 348(21), 2082-2090 (2003).
94. Layman DK, Baum JI: Dietary protein impact on glycemic control during weight loss. J. Nutr. 134(4), 968S-973S (2004).
95. Layman DK, Shiue H, Sather C et al.: Increased dietary protein modifies glucose and insulin homeostasis in adult women during weight loss. J. Nutr. 133(2), 405-410 (2003).
96. Layman DK, Evans E, Baum JI et al.: Dietary protein and exercise have additive effects on body composition during weight loss in adult women. J. Nutr. 135(8), 1903-1910 (2005).
97. Parker B, Noakes M, Luscombe N et al.: Effect of a high-protein, high-monounsaturated fat weight loss diet on glycemic control and lipid levels in Type 2 diabetes. Diabetes Care 25(3), 425-430 (2002).
98. Piatti PM, Monti F, Fermo I et al.: Hypocaloric high-protein diet improves glucose oxidation and spares lean body mass: comparison to hypocaloric high-carbohydrate diet. Metabolism 43(12), 1481-1487 (1994).
99. Skov A, Toubro S, Ronn B et al.: Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int. J. Obes. 23, 528-536 (1999).
100. Klaus S: Increasing the protein: carbohydrate ratio in a high-fat diet delays the development of adiposity and improves glucose homeostasis in mice. J. Nutr. 135(8), 1854-1858 (2005).
101. Lacroix M, Gaudichon C, Martin A et al.: A long-term high-protein diet markedly reduces adipose tissue without major side effects in Wistar male rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287(4), R934-R942 (2004).
102. Stock MJ: Gluttony and thermogenesis revisited. Int. J. Obes. Relat. Metab. Disord. 23(11), 1105-1117 (1999).
103. Levine JA, Eberhardt NL, Jensen MD: Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 283(5399), 212-214 (1999).
104. Hamilton TS: The heat increments of diets balanced and unbalanced with respect to protein. J. Nutr. 17(6), 583-599 (1939).
105. Rothwell NJ, Stock MJ: Influence of carbohydrate and fat intake on diet-induced thermogenesis and brown fat activiiy in rats fed low protein diets. J. Nutr. 117(10), 1721-1726 (1987).
106. Kevonian AV, Vander Tuig JG, Romsos DR: Consumption of a low protein diet increases norepinephrine turnover in brown adipose tissue of adult rats. J. Nutr. 114(3), 543-549 (1984).
107. Miller DS, Mumford P: Gluttony. 1. An experimental study of overeating low- or high-protein diets. Am. J. Clin. Nutr. 20(11), 1212-1222 (1967).
108. Young B, Saville E, Rothwell NJ et al.: Effect of diet and cold exposure on norepinephrine turnover in brown adipose tissue of the rat. J. Clin. Invest. 69(5), 1061-1071 (1982).
109. Tome D: Protein, amino acids and the control of food intake. Br. J. Nutr. 92(Suppl. 1), S27-S30 (2004).
110. Blouet C, Mariotti F, Zout-Marniche D et al.: The reduced energy intake of rats fed a high-protein low-carbohydrate diet explains the lower fat deposition, but macronutrient substitution accounts for the improved glycemic control. J. Nutr. 136(7), 1849-1854 (2006).
111. Pichon L, Huneau JF, Fromentin G et al.: A high-protein, high-fat, carbohydrate-free diet reduces energy intake, hepatic lipogenesis, and adiposity in rats. J. Nutr. 136(5), 1256-1260 (2006).
112. Johnston CS, Tjonn SL, Swan PD: High-protein, low-fat diets are effective for weight loss and favorably alter biomarkers in healthy adults. J. Nutr. 134(3), 586-591 (2004).
113. Krieger JW, Sitren HS, Daniels MJ et al.: Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression 1. Am. J. Clin. Nutr. 83(2), 260-274 (2007).
114. Due A, Toubro S, Skov AR et al.: Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int. J. Obes. Relat. Metab. Disord. 28(10), 1283-1290 (2004).
115. Verhoef P, van Vliet T, Olthof MR et al.: A high-protein diet increases postprandial but not fasting plasma total homocysteine concentrations: a dietary controlled, crossover trial in healthy volunteers. Am. J. Clin. Nutr. 82(3), 553-558 (2005).
116. Halton TL, Willett WC, Liu S et al.: Low-carbohydrate-diet score and the risk of coronary heart disease in women. N. Engl. J. Med. 355(19), 1991-2002 (2006).
117. Tang QQ, Otto TC, Lane MD: CCAAT/enhancer-binding protein β is required for mitotic clonal expansion during adipogenesis. J. Steroid Biochem. Mol. Biol. 100(3), 850-855 (2003).
118. Farmer SR: Transcriptional control of adipocyte formation. Cell Metab. 4(4), 263-273 (2006).
119. Hansen JB, Kristiansen K: Regulatory circuits white versus brown adipocyte differentiation. Biochem. J. 398(2), 153-168 (2006).
120. Rosen ED, MacDougald OA: Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7(12), 885-896 (2006).
121. Borman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. J. Steroid Biochem: Mol. Biol. 94(9), 4312-4317 (1997).
122. Johnson TE, Holloway MK, Vogel R et al.: Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. J. Steroid Biochem. Mol. Biol. 63 (1-3), 1-18 (1997).
123. Kliewer SA, Sundseth SS, Jones SA et al.: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. J. Steroid Biochem. Mol. Biol. 94 (9), 4318-4323 (1997).
124. Yu K, Bayona W, Kallen CB et al.: Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol. Chem. 270(41), 23975-23983 (1995).
125. Barak Y, Nelson MC, Ong ES et al.: PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4(4), 585-595 (1999).
126. Koutnikova H, Cock TA, Watanabe M et al.: Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR hypomorphic mice. J. Steroid Biochem. Mol. Biol. 100(24), 14457-14462 (2003).
127. Kubota N, Terauchi Y, Miki H et al.: PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 (4), 597-609 (1999).
128. Rosen ED, Sarraf P, Troy AE et al.: PPARγ is required for the differentiation of adipose tissue in vivo and in vitro, Mol. Cell 4(4), 611-617 (1999).
129. Keller H, Dreyer C, Medin J et al.: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. J. Steroid Biochem. Mol. Biol. 90(6), 2160-2164 (1993).
130. Gottlicher M, Demoz A, Svensson D et al.: Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor. Biochem. Pharmacol. 46(12), 2177-2184 (1993).
131. De Vos, P, Lefebvre AM, Miller SG et al.: Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ. J. Clin. Invest. 98 (4), 1004-1009 (1996).
132. Hallakou K, Doare L, Foufelle F et al.: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46(9), 1393-1399 (1997).
133. Chaput E, Saladin R, Silvestre M et al.: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 271(2), 445-450 (2000).
134. de Souza CJ, Eckhardt M, Gagen K et al.: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50(8), 1863-1871 (2001).
135. Okuno A, Tamemoto H, Tobe K et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101 (6), 1354-1361 (1998).
136. Lopez IP, Marti A, Milagro FI et al.: DNA microarray analysis of genes differentially expressed in diet-induced (cafeteria) obese rats. Obes. Res. 11 (2), 188-194 (2003).
137. Nakatani T, Kim HJ, Kaburagi Y et al.: A low fish oil inhibits SREBP-1 proteolytic cascade, while a high-fish-oil feeding decreases SREBP-1 mRNA in mice liver: relationship to anti-obesity. J. Lipid Res. 44(2), 369-379 (2003).
138. Huang JT, Welch JS, Ricote M et al.: Interleukin-4-dependent production of PPARγ ligands in macrophages by 12/15-lipoxygenase. Nature 400(6742), 378-382 (1999).
139. Kozak KR, Gupta RA, Moody JS et al.: 15-lipoxygenase metabolism of 2-arachidonylglycerol. Generation of a peroxisome proliferators-activated receptor α. J. Biol. Chem. 277(26), 23278-23286 (2002).
140. Krey G, Braissant O, L'Horset F et al.: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11(6), 779-791 (1997).
141. Nixon JB, Kamitani H, Baek SJ et al.: Evaluation of eicosanoids and NSAIDs as PPARγ ligands in colorectal carcinoma cells. Prostaglandins Leukot. Essent. Fatty Acids 68(5), 323-330 (2003).
142. Shappell SB, Gupta RA, Manning S et al.: 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor γ and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 61(2), 497-503 (2001).
143. Forman BM, Tontonoz P, Chen J et al.: 15-deoxy-δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ, Cell 83(5), 803-812 (1995).
144. Kliewer SA, Lenhard JM, Willson TM et al.: A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83(5), 813-819 (1995).
145. Bell-Parikh LC, Ide T, Lawson JA et al.: Biosynthesis of 15-deoxy-δ12, 14-PGJ2 and the ligation of PPARγ. J. Clin. Invest. 112(6), 945-955 (2003).
146. Madsen L, Petersen RK, Sørensen MB et al.: Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem. J. 375, 539-549 (2003).
147. Amri EZ, Bonino F, Ailhaud G et al.: Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. J. Biol. Chem. 270(5), 2367-2371 (1995).
148. Barak Y, Liao D, He W et al.: Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. J. Steroid Biochem. Mol. Biol. 99(1), 303-308 (2002).
149. Peters JM, Lee SST, Li W et al.: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell Biol. 20(14), 5119-5128 (2000).
150. Hansen JB, Zhang H, Rasmussen TH et al.: Peroxisome proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276(5), 3175-3182 (2001).
151. Wang YX, Lee CH, Tiep S et al.: Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113(2), 159-170 (2003).
152. Westergaard M, Henningsen J, Svendsen ML et al.: Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol. 116(5), 702-712 (2001).
153. Madsen L, Guerre-Millo M, Flindt EN et al.: Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. J. Lipid Res. 43(5), 742-750 (2002).
154. Holst D, Luquet S, Nogueira V et al.: Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta 1633(1), 43-50 (2003).
155. Costet P, Legendre C, More J et al.: Peroxisome proliferator-activated receptor α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273(45), 29577-29585 (1998).
156. Poynter ME, Daynes RA: Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-ΚB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273(49), 32833-32841 (1998).
157. WHO: Diet, Nutrition and the Prevention of Chronic Diseases. WHO Technical Report Series 916, Geneva, Switzerland (2003).
158. Luquet S, Lopez-Soriano J, Holst D et al.: Roles of peroxisome proliferator-activated receptor δ (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 86(11); 833-837 (2004).
159. Patsouris D. Reddy JK, Muller M et al.: Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression. Endocrinology 147(3), 1508-1516 (2006).
160. Brun RP, Tontonoz P, Forman BM et al.: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10(8), 974-984 (1996).
161. Guerre-Millo M. Gervois P. Raspe E et al.: Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275(22), 16638-16642 (2000).
162. Mancini FP, Lanni A, Sabatino L et al.: Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese is. FEBS Lett. 491(1-2), 154-158 (2001).
163. Xu HE, Lambert MH, Montana VG et al.: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol. Cell 3(3), 397-403 (1999).
164. Lin Q, Ruuska SE, Shaw NS et al.: Ligand selectivity of the peroxisome proliferator-activated receptor α. Biochemistry 38(1), 185-190 (1999).
165. Ren B, Thelen AP, Peters JM et al.: Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor α. J. Biol. Chem. 272(43), 26827-26832 (1997).
166. Wong SH, Nestel PJ, Trimble RP et al.: The adaptive effects of dietary fish and safflower oil on lipid and lipoprotein metabolism in perfused rat liver. Biochim. Biophys. Acta 792(2), 103-109 (1984).
167. Takeuchi H, Nakamoto T, Mori Y et al.: Comparative effects of dietary fat types on hepatic enzyme activities related to the synthesis and oxidation of fatty acid and to lipogenesis in rats. Biosci. Biotechnol. Biochem. 65(8), 1748-1754 (2001).
168. Rustan AC, Christiansen EN, Drevon CA: Serum lipids, hepatic glycerolipid metabolism and peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids. Biochem. J. 283(Pt2), 333-339 (1992).
169. Berthou L, Saladin R, Yaqoob P et al.: Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur. J. Biochem. 232(1), 179-187 (1995).
170. Dallongeville J, Bauge E, Tailleux A et al.: Peroxisome proliferator-activated receptor α is not rate-limiting for the lipoprotein-lowering action of fish oil. J. Biol. Chem. 276(7), 4634-4639 (2001).
171. Hua X, Wu J, Gokistein JL et al.: Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 25(3), 667-673 (1995).
172. Shimomura I, Shimano H, Horton JD et al.: Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J. Clin. Invest. 99(5), 838-845 (1997).
173. Yokoyama C, Wang X, Briggs MR et al.: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75(1), 187-197 (1993).
174. Shimomura I, Hammer RE, Richardson JA et al.: Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Gener Dev. 12(20), 3182-3194 (1998).
175. Horton JD, Shimomura I, Ikemoto S et al.: Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278(38), 36652-36660 (2003).
176. Liang G, Yang J, Horton JD et al.: Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277(11), 9520-9528 (2002).
177. Shimano H, Horton JD, Shimomura I et al.: Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and In cultured cells. J. Clin. Invest. 99(5), 846-854 (1997).
178. Shimano H, Shimomura I, Hammer RE et al.: Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J. Clin. Invest. 100(8), 2115-2124 (1997).
179. Shillabeer G, Hornford J, Forden JM et al.: Hepatic and adipose tissue lipogenic enzyme mRNA levels are suppressed by high fat diets in the rat. J. Lipid Res. 31(4), 623-631 (1990).
180. Madsen L, Petersen RK, Kristiansen K: Regulation of adipocyte
181. Petersen RK, Jorgensen C, Rustan AC et al.: Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expression of cyclooxygenases. J. Lipid Res. 44(12), 2320-2330 (2003).
182. Ou J, Tu H, Shan B et al.: Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c ( SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. J. Steroid Biochem. Mol. Biol. 98(11), 6027-6032 (2001).
183. Yoshikawa T, Shimano H, Yahagi N et al.: Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 277(3), 1705-1711 (2002).
184. Kuhajda FP, Landree LE, Ronnett GV: The connections between C75 and obesity drug-target pathways. Trends Pharmacol. Sci. 26(11), 541-544 (2005).
185. Hu Z, Dai Y, Prentki M et al.: A role for hypothalamic malonyl-CoA in the control of food intake. J. Biol. Chem. 280(48), 39681-39683 (2005).
186. Thupari JN, Landree LE, Ronnett GV et al.: C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. J. Steroid Biochem. Mol. Biol. 99(14), 9498-9502 (2002).
187. Schmid B, Rippmann JF, Tadayyon M et al.: Inhibition of fatty acid synthase prevents preadipocyte differentiation. Biochem. Biophys. Res. Commun. 328(4), 1073-1082 (2005).
188. Diraison F, Yankah V, Letexier D et al.: Differences in the regulation of adipose tissue and liver lipogenesis by carbohydrates in humans. J. Lipid Res. 44(4), 846-853 (2003).
189. Horton JD, Bashmakov Y, Shimomura I et al.: Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. J. Steroid Biochem. Mol. Biol. 95(11), 5987-5992 (1998).
190. Kim JB, Sarraf P, Wright M et al.: Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest. 101(1), 1-9 (1998).
191. Shimomura I, Bashmakov Y, Horton JD: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274(42), 30028-30032 (1999).
192. Peet DJ, Turley SD, Ma W et al.: Cholesterol and bile acid metabolism are impared in mice lacking the nuclear receptor LXRα. Cell 93, 693-704 (1998).
193. Stulnig TM, Steffensen KR, Gan H et al.: Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol. Pharmacol. 62, 1299-1305 (2002).
194. Tobin KAR, Ulven SM, Schuster GU et al.: Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J. Biol. Chem. 277(12), 10691-10697 (2002).
195. Dalen KT, Ulven SM, Bamberg K et al.: Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor α. J. Biol. Chem. 278(48), 48283-48291 (2003).
196. Mitro N, Mak PA, Vargas L et al.: The nuclear receptor LXR is a glucose sensor. Nature 445(7124), 219-223 (2007).
197. He Z, Jiang T, Wang Z et al.: Modulation of carbohydrate response element-binding protein gene expressio.n in 3T3-L1 adipocytes and rat adipose time. Am. J. Physiol. Endocrinol. Metab. 287(3), E424-E430 (2004).
198. Iizuka K, Bruick RK, Liang G et al.: Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl Acad. Sci. USA 101(19), 7281-7286 (2004).
199. Iizuka K, Miller B, Uyeda K: Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice. Am. J. Physiol. Endocrinol. Metab. 291(2), E358-E364 (2006).
200. Tsukiyama-Kohara K, Poulin F, Kohara M et al.: Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat. Med. 7(10), 1128-1132 (2001).
201. Fox HL, Kimball SR, Jefferson LS et al.: Amino acids stimulate phosphorylation of p70S6k and organization of rat adipocytes into multicellular clusters. Am. J. Physiol. Cell Physiol. 274(1), C206-C213 (1998).
202. Roh C, Han J, Tzatsos A et al.: Nutrient-sensing mTOR-mediated pathway regulates leptin production in isolated rat adipocytes. Am J. Physiol. Endocrinol. Metab. 284(2), E322-E330 (2003).
203. Lynch CJ, Hutson SM, Patson BJ et al.: Tissue-specific effects of chronic dietary leucine and norleucine supplementation on protein synthesis in rats. Am. J. Physiol. Endocrinol. Metab. 283(4), E824-E835 (2002).
204. Lynch CJ, Paton BJ, Anthony J et al.: Leucine is a direct-acting nutrient signal that regulates protein synthesis in adipose tissue. Am. J. Physiol. Endocrinol. Metab. 283(3), E503-E513 (2002).
205. Fox HL, Pham PT, Kimball SR et al.: Amino acid effects on translational repressor 4E-BP1 are mediated primarily by L-leucine in isolated adipocytes. Am. Physiol. Cell Physiol. 275(5), C1232-C1238 (1998).
206. Yeh W, Bierer BE, McKnight SL: Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 Cells. J. Steroid Biochem. Mol. Biol. 92(24), 11086-11090 (1995).
207. Calkhoven CF, Muller C, Leutz A: Translational control of C/EBPα and C/EBPβ isoform expression. Genes Dev. 14(15), 1920-1932 (2000).
208. Lin TA, Kong X, Saltiel AR et al.: Control of PHAS-I by insulin in 3T3-L1 adipocytes. J. Biol. Chem. 270(31), 18531-18538 (1995).
209. Le Bacquer O, Petroulakis E, Paglialunga S et al.: Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J. Clin. Invest. 117(2), 387-396 (2007).
210. Batterham RL, Heffron H, Kapoor S et al.: Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 4(3), 223-233 (2006).
211. Chakravarty K, Hanson R: Insulin regulation of phosphoenolpyruvate carboxykinase-c gene transcription: the role of sterol regulatory element-binding protein 1c. Nutr. Rev. 65(6 Pt 2). S47-S56 (2007).
212. Cherrington AD: The role of hepatic insulin receptors in the regulation of glucose production. J. Clin. Invest. 115(5), 1136-1139 (2005).
213. Cynober LA: Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 18(9), 761-766 (2002).
214. Czech MP, Corvera S: Signaling mechanisms that regulate glucose transport. J Biol. Chem. 274(4), 1865-1868 (1999).
215. Zierler K: Whole body glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 276 (3), E409-E426 (1999).
216. Woerle HJ, Meyer C, Dostou JM et al.: Pathways for glucose disposal after meal ingestion in humans. Am. J. Physiol. Endocrinol. Metab. 284(4), E716-E725 (2003).
217. White MF, Kahn CR: The insulin signaling system. J. Biol. Chem. 269(1), 1-4 (1994).
218. Adams CM: Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic action of glucocorticoids. J. Biol. Chem. 282, 16744-16753 (2007).
219. Um S, D'Alessio D, Thomas G: Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 3(6), 393-402 (2006).
220. Moore MC, Cherrington AD, Wasserman DH: Regulation of hepatic and peripheral glucose disposal. Best Pract. Res. Clin. Endocrinol. Metab. 17(3), 343-364 (2003).
221. Nevado C, Valverde AM, Benito M: Role of insulin receptor in the regulation of glucose uptake in neonatal hepatocytes. Endocrinology, 147(8), 3709-3718 (2006).
222. Im SS, Kwon SK, Kang SY et al.: Regulation of GLUT4 gene expression by SREBP-1c in adipocytes. Bioechem. J. 399(1), 131-139 (2006).
223. Foufelle F, Ferr P: New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366(2), 377-391 (2002).
224. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109(9), 1125-1131 (2002).
225. Chen G, Liang G, Ou J et al.: Central role for liver X receptor in Insulin-mediated activation of Srebp-1c transcription and stimulation of atty acid synthesis in liver. J. Steroid Biochem. Mol. Biol. 101 (31), 11245-11250 (2004).
226. Lazar MA, Willson TM: Sweet dreams for LXR. Cell Metab. 5 (3), 159-161 (2007).
227. Yamashita H, Takenoshita M, Sakurai M et al.: A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. J. Steroid Biochem. Mol. Biol. 98(16), 9116-9121 (2001).
228. Onuma H, Makino H, Osawa H et al.: Mitogen-activated protein kinase and p70 ribosomal protein S6 kinase are not involved in the insulin-dependent stimulation of cAMP phosphodiesterase kinase in rat adipocytes. Biochim. Biophys. Acta 1402(2), 197-208 (1998).
229. Smith CJ, Vasta V, Degerman E et al.: Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin- and cAMP dependent activation by phosphorylation. J. Biol. Chem. 266(20), 13385-13390 (1991).
230. Kono T, Barham FW: Effects of insulin on the levels of adenosine 3′:5′-monophosphate and lipolysis in isolated rat epididymal fat cells. J Biol. Chem. 248(21), 7417-7426 (1973).
231. Makino H, Suzuki T, Kajinuma H et al.: The role of insulin-sensitive phosphodiesterase in insulin action. Adv. Second Messenger Phosphoprotein Res. 25, 185-199 (1992).
232. Manganiello V, Vaughan M: An effect of insulin on cyclic adenosine 3′:5′-monophosphate phosphodiesterase activity in fat cells. J. Biol. Chem. 248(20), 7164-7170 (1973).
233. Beebe SJ, Redmon JB, Blackmore PF et al.: Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocyte glycogenolysis. J Biol. Chem. 260(29), 15781-15788 (1985).
234. Witters LA, Moriarity, D, Martin DB: Regulation of hepatic acetyl coenzyme A carboxylase by insulin and glucagon. J. Biol. Chem. 254(14), 6644-6649 (1979).
235. McGarry JD, Mannaerts GE Foster DW: A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin. Invest. 60(1), 265-270 (1977).
236. Fanelli CG, Porcellati F, Rossetti P et al.: Glucagon: the effects of its excess and deficiency on insulin action. Nutr Metab. Cardiovasc. Dis. 16(Suppl. 1), S28-S34 (2006).
237. Estall JL, Drucker DJ: Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 12(14), 1731-1750 (2006).
238. Puigserver P, Rhee J, Donovan J et al.: Insulin-regulated hepatic gluconeogenesis through FOX01-PGC-lα interaction. Nature 423(6939), 550-555 (2003).
239. Postic C, Dentin R, Girard J: Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 30(5), 398-408 (2004).
240. Kaloyianni M, Freedland RA: Contribution of several amino acids and lactate to gluconeogenesis in hepatocytes isolated from rats fed various diets. J. Nutr. 120(1), 116-122 (1990).
241. Gustavson SM, Chu CA, Nishizawa M et al.: Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. Am. J Physiol. Endocrinol. Metab. 284(4), E695-E707 (2003).
242. Gustavson SM, Chu CA, Nishizawa M et al.: Glucagon's actions are modified by the combination of epinephrine and gluconeogenic precursor infusion. Am. J. Physiol. Endocrinol. Metab. 285(3), E534-E544 (2003).
243. Feng P, Pozefsky T, Marliss E et al.: Alanine: key role in gluconeogenesis. Science 167(920), 1003-1004 (1970).
244. Porcellati F, Pampanelli S, Rossetti P et al.: Effect of the amino acid alanine on glucagon secretion in non-diabetic and Type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. Diabetologia 50(2), 422-430 (2007).
245. Wiethop BV, Cryer PE: Glycemic actions of alanine and terbutaline in IDDM. Diabetes Care 16(8), 1124-1130 (1993).
246. Jarrousse C, Lardeux B, Bourdel G et al.: Portal insulin and glucagon in rats fed proteins as a meal: immediate variations and circadian modulations. J. Nutr. 110(9), 1764-1773 (1980).
247. Fafournoux P, Réemésy C, Demigné C: Stimulation of amino acid transport into liver cells from rats adapted to a high-protein diet. Biochem. J. 206(1). 13-18 (1982).
248. Azzout B, Chanez M, Bois-Joyeux B et al.: Gluconeogenesis from dihydroxyacetone in rat hepatocytes during the shift from a low protein, high carbohydrate to a high pmtein, carbohydrate-free diet. J. Nutr. 114(11), 2167-2178 (1984).
249. Boisjoyeux B, Chanez M, Azzout B et al.: Comparison between starvation and consumption of a high protein diet: plasma insulin and glucagon and hepatic activities of gluconeogenic enzymes during the first 24 hours, Diabete Metab. 12(1), 21-27 (1986).
250. Linn T, Santosa B, Grönemeyer D et al.: Effect of long-term dietary protein intake on glucose metabolism in humans. Diabetologia 43(10), 1257-1265 (2000).
251. Handlogten ME, Kilberg MS: Induction and decay of amino acid transport in the liver. Turnover of transport activity in isolated hepatocytes after stimulation by diabetes or glucagon. J. Biol. Chem. 259(6), 3519-3525 (1984).
252. Mallette LE, Exton JH, Park CR: Effects of glucagon on amino acid transport and utilization in the perfused rat liver. J. Biol. Chem. 244(20), 5724-5728 (1969).
253. Snodgrass PJ, Lin RC, Muller WA et al.: Induction of urea cycle enzymes of rat liver by glucagon. J. Biol. Chem. 253(8), 2748-2753 (1978).
254. Lacey JH, Bradford NM, Joseph SK et al.: Increased activity of phosphate-dependent glutaminase in liver mitochondria as result of glucagon treatment of rats. Biochem. J. 194(1), 29-33 (1981).
255. Azzout-Marniche D, Gaudichon C, Blouet C et al.: Liver glyconeogenesis: a pathway to cope with postprandial amino acid excess in high-protein fed rats? Am. J. Physiol. Regul. Integr. Comp. Physiol. 292(4), R1400-R1407 (2007).
256. Remesy C, Demigne C: Impaired lactate utilization in livers of rats fed high protein diets. J. Nutr. 112(1), 60-69 (1982).
257. Bertin E, Amer P, Bolinder J et al.: Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J. Clin. Endocrinol. Metab. 86(3), 1229-1234 (2001).
258. Langin D: Control of fatty acid and glycerol release in adipose tissue lipolysis. CR Biol. 329(8), 598-607 (2006).
259. Jensen MD, Heiling VJ, Miles JM: Effects of glucagon on free fatty acid metabolism in humans, J. Clin. Endocrinol. Metab. 72 (2), 308-315 (1991).
260. Wu MS, Jeng CY, Hollenbeck CB et al.: Does glucagon increase plasma free fatty acid concentration in humans with normal glucose tolerance? J. Clin. Endocrinol. Metab. 70(2), 410-416 (1990).
261. Carmen GY, Victor SM: Signalling mechanisms regulating lipolysis. Cell Signal. 18(4), 401-408 (2006).
262. Holm C: Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans. 31(Pt 6), 1120-1124 (2003).
263. Nelson DL, Gehlert DR: Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 29(1), 49-60 (2006).
264. Palmiter RD: Is dopamine a physiologically relevant mediator of feeding behavior? Trends Neurosci. 30(8), 375-381 (2007).
265. Wellman PJ: Norepinephrine and the control of food intake. Nutrition 16(10), 837-842 (2000).
266. Cannon B, Nedergaard J: Brown adipose tissue: function and physiological significance. Physiol. Rev. 84(1), 277-359 (2004).
267. Collins S, Cao W, Robidoux J: Learning new tricks from old dogs: β-adrenergic receptors teach new lessons on firing up adipose tissue metabolism. Mol. Endocrinol. 18(9), 2123-2131 (2004).
268. Langin D: Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol. Res. 53(6), 482-491 (2006).
269. Lovenberg W, Kuhn DM: Role of hydroxylase cofactor in serotonin biosynthesis. Psychopharmacol. Bull. 14(4), 44-46 (1978).
270. Boado RJ, Li JY, Nagaya M et al.: Selective expression of the large neutral amino acid transporter at the blood-brain barrier. J. Steroid Biochem. Mol. Biol. 96(21), 12079-12084 (1999).
271. Hawkins RA, O'Kane RL, Simpson IA et al.: Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 136(1), 218S-226S (2006).
272. Fernstrom JD, Wurtman RJ: Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 178(59), 414-416 (1972).
273. Oldendorf WH: Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221(6), 1629-1639 (1971).
274. Fernstrom JD, Faller DV: Neutral amino acids in the brain: changes in response to food ingestion. J. Neurochem. 30(6), 1531-1538 (1978).
275. Le Masurier M, Oldenzeil W, Lehman C et al.: Effect of acute tyrosine depletion in using a branched chain amino-acid mixture on dopamine neurotransmission in the rat brain. Neuropsychopharmacology 31(2), 310-317 (2005).
276. Biggio G, Porceddu ML, Gessa GL: Decrease of homovanillic, dihydroxyphenylacetic acid and cyclic-adenosine-3′,5′-monophosphate content in the rat caudate nucleus induced by the acute administration of an aminoacid mixture lacking tyrosine and phenylalanine. J. Neurochem. 26(6), 1253-1255 (1976).
277. Fernstrom MHFJD: Acute tyrosine depletion reduces tyrosine hydroxylation rate in rat central nervous system. Life Sci. 57(9), PL97-PL102 (1995).
278. McTavish SFB, Cowen PJ, Sharp T: Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology 141(2), 182-188 (1999).
279. Palmour RM, Ervin FR, Baker GB et al.: An amino acid mixture deficient in phenylalanine and tyrosine reduces cerebrospinal fluid catecholamine metabolites and alcohol consumption in vervet monkeys. Psychopharmacology 136(1), 1-7 (1998).
280. 11C]raclopride study in healthy men. Neuropsychopharmacology 29(2), 427-432 (2004).
281. Leyton M, Pun VK, Benkelfat C et al.: A new method for rapidly and simultaneously decreasing serotonin and catecholamine synthesis in humans. J. Psychiatry Neurosci. 28(6), 464-467 (2003).
282. Agharanya JC, Alonso R, Wurtman RJ: Changes in catecholamine excretion after short-term tyrosine ingestion in normally fed human subjects. Am. J. Clin. Nutr. 34(1), 82-87 (1981).
283. Alonso R, Agharanya JC, Wurtman RJ: Tyrosine loading enhances catecholamine excretion by rats. J. Neural. Transm. 49(1-2), 31-43 (1980).
284. Morton GJ, Cummings DE, Baskin DG et al.: Central nervous system control of food intake and body weight. Nature 443(7109), 289-295 (2006).
285. Jackson HC, Bearham MC, Hutchins LJ et al.: Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br. J. Pharmacol. 121(8), 1613-1618 (1997).
286. Bartness TJ, Kay Song C, Shi H et al.: Brain-adipose tissue cross talk. Proc. Nutr. Soc. 64(1), 53-64 (2005).
287. Fekete C, Marks DL, Sarkar S et al.: Effect of agouti-related protein in regulation of the hypothalamic-pituitary-thyroid axis in the melanocortin 4 receptor knockout mouse. Endocrinology 145(11), 4816-4821 (2004).
288. Joseph-Bravo P: Hypophysiotropic thyrotropin-releasing hormone neurons as transducers of energy homeostasis. Endocrinology 145(11), 4813-4815 (2004).
289. Lechan RM, Fekete C: The TRH neuron: a hypothalamic integrator of energy metabolism. In Hypothalamic Integration of Energy Metabolism, Proceedings of the 24th International Summer School of Brain Research, Held at the Royal Netherlands Academy of Arts and Sciences. Elsevier, Amsterdam, The Netherlands 209-235 (2006).
290. Branco M, Ribeiro M, Negrao N et al.: 3,5,3′-triiodothyronine actively stimulates UCP in brown fat under minimal sympathetic activity. Am. J. Physiol. Endocrinol. Metab. 276(), E179-E187 (1999).
291. Guerra C, Roncero C, Porras A et al.: Triiodothyronine induces the transcription of the uncoupling protein gene and stabilizes its mRNA in fetal rat brown adipocyte primary cultures. J. Biol. Chem. 271(4), 2076-2081 (1996).
292. Rubio A, Raasmaja A, Silva JE: Thyroid hormone and norepinephrine signaling in brown adipose tissue. II: differential effects of thyroid hormone on β 3-adrenergic receptors in brown and white adipose tissue. Endocrinology 136(8), 3277-3284 (1995).
293. Granneman JG, Burnazi M, Zhu Z et al.: White adipose tissue contributes to UCP1-independent thermogenesis. Am. Physiol. Endocrinol. Metab. 285(6), E1230-E1236 (2003).
294. Cinti S: The role of brown adipose tissue in human obesity. Nutr. Metab. Cardiovasc. Dis. 16(8), 569-574 (2006).
295. Himms-Hagen J: Does brown adipose tissue (BAT) have a role in the physiology or treatment of human obesity? Rev. Endocr. Metab. Disord. 2(4), 395-401 (2001).
296. Oberkofler H, Dallinger G, Liu YM et al.: Uncoupling protein gene: quantification of expression levels in adipose tissues of obese and non-obese humans. J. Lipid Res. 38(10), 2125-2133 (1997).
297. Leppaluoto J, Paakkonen T, Korhonen I et al.: Pituitary and autonomic responses to cold exposures in man. Acta Physiol. Scand. 184(4), 255-264 (2005).
298. Huttunen P, Hirvonen J, Kinnula V: The occurrence of brown adipose tissue in outdoor workers. Eur. J. Appl. Physiol. Occup. Physiol. 46(4), 339-345 (1981).
299. Lean ME, James WP, Jennings G et al.: Brown adipose tissue in patients with phaeochromocytoma. Int. J. Obes. 10(3), 219-227 (1986).
300. Ricquier D, Nechad M, Mory G: Ultrastructural and biochemical characterization of human brown adipose tissue in pheochromocytoma. J. Clin. Endocrinol. Metab. 54(4), 803-807 (1982).
301. Evans D, Minouchehr S, Hagemann G et al.: Frequency of and interaction between polymorphisms in the β3-adrenergic receptor and in uncoupling proteins 1 and 2 and obesity in Germans. Int. J. Obes. Relat. Metab. Disord. 24(10), 1239-1245 (2000).
302. Park HS, Kim Y, Lee C: Single nucleotide variants in the β2-adrenergic and β3-adrenergic receptor genes explained 18.3% of adolescent obesity variation. J. Hum. Gen. 50(7), 365-369 (2005).
303. Valve R, Heikkinen S, Rissanen A et al.: Synergistic effect of polymorphisms in uncoupling protein 1 and β3-adrenergic receptor genes on basal metabolic rate in obese Finns. Diabetologia 41(3), 357-361 (1998).
304. Simonsen L, Bulow J, Madsen J et al.: Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am. J. Physiol. Endocrinol. Metab. 263(5), E850-E855 (1992).
305. Farooqi IS, O'Rahilly S: Monogenic human obesity syndromes. Recent Prog. Horm. Res. 59(1), 409-424 (2004).
306. Amigo I, Mendez C: Effects of diets and their role in weight control. Psychol. Health Med. 12(3), 321-327 (2007).
307. Doucet E, Imbeault P, St-Pierre S et al.: Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. Int. J. Obes. Relat. Metab. Disord. 24(7), 906-914 (2000).
308. Cummings DE, Overduin J: Gastrointestinal regulation of food intake. J. Clin. Invest. 117(1), 13-23 (2007).
309. Dham S, Banerji MA: The brain-gut axis in regulation of appetite and obesity. Pediatr. Endocrinol. Rev. 3(Suppl 4), 544-554 (2006).
310. Dhillo WS: Appetite regulation: an overview. Thyroid 17(5), 433-435 (2007).
311. Murphy KG, Bloom SR: Gut hormones and the regulation of energy homeostasis. Nature 444(7121), 854-859 (2006).
312. Moran TH: Gut peptide signaling in the controls of food intake. Obesity Res. 14(Suppl. 5), 250S-253S (2006).
313. Trigazis L, Orttmann A, Anderson GH: Effect of a cholecystokinin-A receptor blocker on protein-induced food intake suppression in rats. Am. J. Physiol Regul. Integr. Comp. Physiol. 272(6), R1826-R1833 (1997).
314. Kojima M, Hosoda H, Date Y et al.: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762), 656-660 (1999).
315. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 407(6806), 908-913 (2000).
316. Wortley KE, del Rincon JP, Murray JD et al.: Absence of ghrelin protects against early-onset obesity. J. Clin. Invest. 115(12), 3573-3578 (2005).
317. Zigman JM, Nakano Y, Coppari R et al.: Mice lacking ghrelin receptors resist the development of diet-induced obesity. J. Clin. Invest. 115(12), 3564-35672 (2005).
318. Gruninger TR, LeBoeuf B, Liu Y et al.: Molecular signaling involved in regulating feeding and other motivated behaviors. Mol. Neurobiol. 35(1), 1-20 (2007).
319. Pages N, Orosco M, Routh C et al.: Refeeding after 72 hour fasting alters neuropeptide Y and manoamines in various cerebral areas in the rat. Comp. Biochem. Physiol. Comp. Physiol. 106(4), 845-849 (1993).
320. Pages N, Orosco M, Rouch C et al.: Fasting affects more markedly neuropeptide Y than monoamines in the rat brain. Pharmacol. Biochem. Behav. 44(1), 71-75 (1993).
321. Qian S, Chen H, Weingarth D et al.: Neither agouti-related protein nor neuropeptide Y is critically required for the regulation of energy homeostasis in mice. Mol. Cell. Biol. 22(14), 5027-5035 (2002).
322. Kushi A, Sasai H, Koizumi H et al.: Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. J. Steroid Biochem. Mol. Biol. 95 (26), 15659-15664 (1998).
323. Segal-Lieberman G, Trombly DJ, Juthani V et al.: NPY ablation in C57BL/6 mice leads to mild obesity and to an impaired refeeding response to fasting. Am. J. Physiol. Endocrinol. Metab. 284(6), E1131-E1139 (2003).
324. Date Y, Shimbara T, Koda S et al.: Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. Cell Metab. 4(4), 323-331 (2006).
325. Theander-Carrillo C, Wiedmer P, Cettour-Rose P et al.: Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 116(7), 1983-1993 (2006).
326. Kinzig KP, Hargrave SL, Hyun J et al.: Energy balance and hypothalamic effects of a high-protein/low-carbohydrate diet. Physiol. Behav. 92(3), 454-460 (2007).
327. Li G, Mobbs CV, Scarpace PJ: Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 52(8), 1951-1957 (2003).
328. Muccioli G, Pons N, Ghe C et al.: Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur. J. Pharmacol. 498(1-3), 27-35 (2004).
329. Gomez G, Englander EW, Greeley GH: Nutrient inhibition of ghrelin secretion in the fasted rat. Regul. Pept. 117(1), 33-36 (2004).
330. Vallejo-Cremades MT, Gomez-Garcia L, Chacatas-Cortesao M et al.: Enriched protein diet-modified ghrelin expression and secretion in rats. Regul. Pept. 121(1-3), 113-119 (2004).
331. Sanchez J, Oliver P. Palou A et al.: The inhibition of gastric ghrelin production by food intake in rats is dependent on the type of macronutrient. Endocrinology 145(11), 5049-5055 (2004).
332. Batterham RL, Cowley MA, Small CJ et al.: Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418(6898), 650-654 (2002).
333. Lee HM, Wang G, Englander EW et al.: Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 143(1), 185-190 (2002).
334. Moesgaard SG, Ahren B, Carr RD et al.: Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach. Regul. Pept. 120(1-3), 261-267 (2004).
335. Asakawa A, Inul A, Kaga T et al.: Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 52(7), 947-952 (2003).
336. Beck B, Richy S, Stricker-Krongrad A: Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci. 76(4), 473-478 (2004).
337. Zorrilla EP, Iwasaki S, Moss JA et al.: Vaccination against weight gain. Proc. Natl Acad. Sci. USA 103(35), 13226-13231 (2006).
338. Tschop M, Weyer C, Tataranni PA et al.: Circulating ghrelin levels are decreased in human obesity. Diabetes 50(4), 707-709 (2001).
339. Ariyasu H, Takaya K, Hosoda H et al.: Delayed short-term secretory regulation of ghreltn in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinolgy 143(9), 3341-3450 (2002).
340. Lindqvist A, de la Cour CD, Stegmark A et al.: Overeating of palatable food is associated with blunted leptin and ghrelin responses. Regul. Pept. 130(3), 123-132 (2005).
341. West DB, Fey D, Woods SC: Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 246(5), R776-R787 (1984).
342. Crawley JN, Beinfeld MC: Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302, 703-706 (1983).
343. Asin KE, Gore J, Bednarz L et al.: Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. 571(1), 169-174 (1992).
344. Corp ES, Curcio M, Gibbs J et al.: The effect of centrally administered CCK-receptor antagonists on food intake in rats. Physiol. Behav. 61(6), 823-827 (1997).
345. Bignon E, Alonso R, Amone M et al.: SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist II: in vivo pharmacological characterization. J. Pharmacol. Exp. Ther. 289(2), 752-761 (1999).
346. Bi S, Ladenheim EE, Schwartz GJ et al.: A role for NPY overexpression in the dorsomedial hypothalamus in hyperphagia and obesity of OLETF rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281(1), R254-R260 (2001).
347. Fan W, Ellacott KLJ, Helatchev IG et al.: Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat. Neurosci. 7(4), 335-336 (2004).
348. Moran TH, Katz LF, Plata-Salaman CR et al.: Disordered food intake and obesity in rats lacking cholecystokinin A receptors Am. J. Physiol. Regul. Integr. Comp. Physiol. 274(3), R618-R625 (1998).
349. Kopin AS, Mathes WF, McBride EW et al.: The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight. J. Clin. Invest. 103(3), 383-391 (1999).
350. Bi S, Chen J, Behles RR et al.: Differential body weight and feeding responses to high-fat diets in rats and mice lacking cholecystokinin 1 receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293(1), R55-R63 (2007).
351. Baranowska B, Radzikowska M, Wasilewska-Dziubinska E et al.: Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes. Metab. 2(2), 99-103 (2000).
352. Bowen J, Noakes M, Clifton PM: Appetite regulatory hormone responses to various dietary proteins differ by body mass index status despite similar reductions in ad libitum energy intake. J. Clin. Endocrinol. Metab. 91(8), 2913-2919 (2006).
353. French SJ, Murray B, Rumsey RDE et al.: Is cholecystokinin a satiety hormone? Correlations of plasma cholecystokinin with hunger, satiety and gastric emptying in normal volunteers. Appetite 21(2), 95-104 (1993).
354. Covasa M, Marcuson JK, Ritter RC: Diminished satiation in rats exposed to elevated levels of endogenous or exogenous cholecystokinin. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280(2), R331-R337 (2001).
355. Covasa M, Ritter RC: Adaptation to high-fat diet reduces inhibition of gastric emptying by CCK and intestinal oleate. Am. J. Physiol. Regul. Integr. Comp. Physiol. 278(1), R166-R170 (2000).
356. Covasa M, Ritter RC: Reduced sensitivity to the satiation effect of intestinal oleate in rats adapted to high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277(1), R279-R285 (1999).
357. Liddle RA, Goldfine ID, Rosen MS et al.: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. 75, 1144-1152 (1985).
358. Hopman WP, Jansen JB, Lamers CB: Comparative study of the effects of equal amounts of fat, protein, and starch on plasma cholecystokinin in man. Scand. J. Gastroenterol. 20, 843-847 (1985).
359. Bowen J, Noakes M, Trenerry C et al.: Energy intake, ghrelin, and cholecystokinin after different carbohydrate and protein preloads in overweight men. J. Clin. Endocrinol. Metab. 91(4), 1477-1483 (2006).
360. Lewis LD, Williams JA: Regulation of cholecystokinin secretion by food, hormones, and neural pathways in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 258(4). G512-G518 (1990).
361. Liddle RA, Green GM, Conrad CK et al.: Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat. Am. J. Physiol. Gastroinvest. Liver Physiol. 251(2), G243-G248 (1986).
362. Sharara AI, Bouras EP, Misukonis MA et al.: Evidence for indirect dietary regulation of cholecystokinin release in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 265(1), G107-G112 (1993).
363. Green GM, Taguchi S, Friestman J et al.: Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat. Am. J. Physiol. Gastrointest. Liver Physiol. 256(6), G1016-G1021 (1989).
364. Douglas BR, Woutersen RA, Jansen JB et al.: The influence of different nutrients on plasma cholecystokinin levels in the rat. Experientia 44, 21-23 (1988).
365. Trigazis L, Vaccarino FJ, Greenwood CE et al.: CCK-A receptor antagonists have selective effects on nutrient-induced food intake suppression in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 276(2), R323-R330 (1999).
366. Bellissimo N, Anderson GH: Cholecystokinin-A receptors are involved in
367. Schwartz GJ, Whitney A, Skoglund C et al.: Decreased responsiveness to dietary fat in Otsuka long-evans Tokushima fatty rats lacking CCK-A receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 277(4), R1144-R1151 (1999).
368. Pupovac J, Anderson GH: Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J. Nutr. 132(9), 2775-2780 (2002).
369. Chelikani PK, Haver AC, Reidelberger RD: Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146(2), 879-888 (2005).
370. Boey D, Lin S, Karl T et al.: Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49(6), 1360-1370 (2006).
371. Schonhoff S, Baggio L, Ratineau C et al.: Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol. Cell Biol. 25(10), 4189-4199 (2005).
372. Challis BG, Pinnock SB, Coll AP et al.: Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. 311, 915-919 (2003).
373. Challis BG, Coll AP, Yeo GSH et al.: Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3-36. J. Steroid Biochem. Mol. Biol. 101(13), 4695-4700 (2004).
374. Halatchev IG, Ellacott KLJ, Fan W et al.: Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145(6), 2585-2590 (2004).
375. Pittner RA, Moore CX, Bhavsar SP et al.: Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 28, 963-971 (2004).
376. Alvarez Bartolomé M, Borque M, Martinez-Sarmiento J et al.: Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes. Surg. 12, 324-327 (2002).
377. Batterham RL, Cohen MA, Ellis SM et al.: Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349(10), 941-948 (2003).
378. Fu-Cheng X, Anini Y, Chariot J et al.: Peptide YY release after intraduodenal, intraileal, and intracolonic administration of nutrients in rats. Pflugers Arch. 431, 66-75 (1995).
379. Dumoulin V, Moro F, Barcelo A et al.: Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 139(9), 3780-3786 (1998).
380. Navarro M, de Fonseca FR, Alvarez E et al.: Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem. 67(5), 1982-1991 (1996).
381. Turton MD, O'Shea D, Gunn I et al.: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560), 69-72 (1996).
382. Donahey JCK, van Dijk G, Woods SC et al.: Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res. 779(1-2), 75-83 (1998).
383. Rodriquez de Fonseca F, Navarro M, Alvarez E et al.: Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49(6), 709-717 (2000).
384. Scrocchi LA, Brown TJ, MaClusky N et al.: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2, 1254-1258 (1996).
385. Knauf C, Cant PD,. Perrin C et al.: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 115(12), 3554-3563 (2005).
386. Flint A, Raben A, Ersboll AK et al.: The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. Relat Metab. Disord. 25(6), 781-792 (2001).
387. Verdich C, Flint A, Gutzwiller JP et al.: A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endrocrinol. Metab. 86(9), 4382-4389 (2001).
388. Druckner J: Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenteroloy 122, 531-544 (2002).
389. Aziz A, Anderson GH: Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats. J. Nutr. 132(5), 990-995 (2002).
390. Herrmann C, Göke R, Richter G et al.: Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56, 117-126 (1995).
391. Ritzel U, Fromme A, Ottleben M et al.: Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetol. 34, 18-21 (1997).
392. Sugiyama K, Manaka H, Kato T et al.: Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 55, 24-28 (1994).
393. Peters CT, Choi YH, Brubaker PL et al.: A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J. Nutr. 131(8), 2164-2170 (2001).
394. Cordier-Bussat M, Bernard C, Levenez F et al.: Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 47(7), 1038-1045 (1998).
395. Iritani N, Sugimoto T, Fukuda H et al.: Oral triacylglycerols regulate plasma glucagon-like peptide-1(7-36) and insulin levels in normal and especially in obese rats. J. Nutr. 129(1), 46-50 (1999).
396. Guthrie JF, Morton JF: Food sources of added sweeteners in the diets of Americans. J. Am. Diet Assoc. 100(1), 43-51 (2000).
397. Cavadini C, Siega-Riz AM, Popkin BM: US adolescent food intake trends from 1965 to 1996. Arch. Dis. Child. 83(1), 18-24 (2000).
398. Malik VS, Schulze MB, Hu FB: Intake of sugar-sweetened beverages and weight gain: a systematic review. Am. J. Clin. Nutr. 84(2). 274-288 (2006).
399. Berger JJ, Barnard RJ: Effect of diet on fat cell size and hormone-sensitive lipase activity. J. Appl. Physiol. 87(1), 227-232 (1999).
400. Ellis RJ, McDonald RB, Stern JS: A diet high in fat stimulates adipocyte proliferation in older (22 month) rats. Exp. Gerontol. 25(2), 141-148 (1990).
401. Klyde BJ, Hirsch J: Increased cellular proliferation in adipose tissue of adult rats fed a high-fat diet. J. Lipid Res. 20(6), 705-715 (1979).
402. Miller WH Jr, Faust IM, Hirsch J: Demonstration of de novo production of adipocytes in adult rats by biochemical and radioautographic techniques. J. Lipid Res. 25(4), 336-347 (1984).
403. Roberts CK, Barnard RJ, Liang KH et al.: Effect of diet on adipose tissue and skeletal muscle VLDL receptor and LPL: implications for obesity and hyperlipidemia. Atherosclerosis 161(1), 133-141 (2002).
404. Shillabeer G, Lau DC: Regulation of new fat cell formation in rats: the role of dietary fats. J. Lipid Res. 35(4), 592-600 (1994).
405. Goldbeter A: A model for the dynamics of human weight cycling. J. Biosci. 31(1), 129-136 (2006).
406. Brownell KD, Greenwood MR, Stellar E et al.: The effects of repeated cycles of weight loss and regain in rats. Physiol. Behav. 38(4), 459-464 (1986).
407. Steen SN, Oppliger RA, Brownell KD: Metabolic effects of repeated weight loss and regain in adolescent wrestlers. JAMA 260(1), 47-50 (1988).
408. Hahn P, Skala JP, Hassanali S: The response of cyclic nucleotide content in liver and brown fat of rats weaned to different diets. J. Nutr. 110(2), 330-334 (1980).
409. Illiano G, Cuatrecasas P: Modulation of adenylate cyclase activity in liver and fat cell membranes by insulin. Science 175(24), 906-908 (1972).
410. Ip MM, Ip C, Tepperman HM et al.: Effect of adaptation to meal-feeding on insulin, glucagon and the cyclic nucleotide-protein kinase system in rats. J. Nutr. 107(5), 746-757 (1977).
411. Manganiello VC, Murad F, Vaughan M: Effects of lipolytic and antipolytic agents on cyclic 3′,5′-adenosine monophosphate n fat cells. J. Biol. Chem. 246(7), 2195-2202 (1971).
412. Henderson L: The national diet and nutrition survey: adult aged 19-64 year. HMSO Edt (2003).
413. Frayling TM, Timpson NJ, Weedon MN et al.: A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316(5826), 889-894 (2007).
414. Rankinen T, Zuberi A, Chagnon YC et al.: The human obesity gene map: the 2005 update. Obesity Res. 14(4), 529-644 (2006).
415. Rankinen T, Bouchard C: Genetics of food intake and eating behavior phenotypes in humans. Annu. Rev. Nutr. 26(1), 413-434 (2006).
416. Tiffin N, Adie E, Turner V et al. i: Computational disease gene identification: a concert of methods prioritizes Type 2 diabetes and obesity candidate genes. Nucleic Acids Res. 34(10), 3067-3081 (2006).
417. Walley AJ, Blakemore AIF, Froguel P: Genetics of obesity and the prediction of risk for health. Hum. Mol. Genet. 15(Suppl. 2), R124-R130 (2006).
418. Pagliassotti MJ, Prach PA, Koppenhafer TA et al.: Changes in insulin action, triglycerides, and lipid composition during sucrose feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 271(5), R1319-R1326 (1996).
419. Storlien LH, Kraegen EW. Jenkins AB et al.: Effects of sucrose vs starch diets on in vivo insulin action, thermogenesis, and obesity in rats. Am. J. Clin. Nutr. 47(3),.420-427 (1988).
420. Shimomura Y, Tamura Y, Suzuki M: Less body fat accumulation in rats fed a safflower oil diet than in rats fed a beef tallow diet. J. Nutr. 120(11), 1291-1296 (1990).
421. Wang H, Storlien LH, Huang XF: Effects of dietary fat types on body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression. Am. J. Physiol. Endocrinol. Metab. 282(6), E1352-E1359 (2002).
422. Minami A, Ishimura N, Sakamoto S et al.: Effect of eicosapentaenoic acid ethyl ester v. oleic acid-rich safflower oil on insulin resistance in Type 2 diabetic model rats with hypertriacylglycerolaemia. Br. J. Nutr. 87(2), 157-162 (2002).
423. Cha SH, Fukushima A, Sakuma K et al.: Chronic docosahexaenoic acid intake enhances expression of the gene for uncoupling protein 3 and affects pleiotropic mRNA levels in skeletal muscle of aged C57BL/6NJcl mice. J. Nutr. 131(10), 2636-2642 (2001).
424. Takahashi Y, Ide T: Dietary n-3 fatty acids affect mRNA level of brown adipose tissue uncoupling protein 1, and white adipose tissue leptin and glucose transporter 4 in the rat. Br. J. Nutr. 84(2), 175-184 (2000).
425. Jang IS, Hwang DY, Chae KR et al.: Role of dietary fat type in the development of adiposity from dietary obesity-susceptible Sprague-Dawley rats. Br. J. Nutr. 89(3), 429-438 (2003).
426. Pellizzon M, Buison. A, Ordiz F Jr et al.: Effects of dietary fatty acids and exercise on body-weight regulation and metabolism in rats. Obes. Res. 10(9), 947-955 (2002).
427. Mater MK, Thelen AP, Pan DA et al.: Sterol response element-binding protein 1c (SREBP1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription. J. Biol. Chem. 274(46), 32725-32732 (1999).
428. Xu J, Nakamura MT. Cho HP et al.: Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J. Biol. Chem. 274(33), 23577-23583 (1999).
429. Kim HJ, Takahashi M, Ezaki O: Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J. Biol. Chem. 274(36), 25892-25898 (1999).
430. Brown JM, Boysen MS, Jensen SS et al.: Isomer-specific regulation of metabolism and PPARγ signaling by CLA in human preadipocytes. J Lipid Res. 44(7), 1287-1300 (2003).
431. Granlund L, Pedersen JI, Nebb HI: Impaired lipid accumulation by trans10, cis12 CLA during adipocyte differentiation is dependent on timing and length of treatment. Biochim. Biophys. Acta 1687(1-3), 11-22 (2005).
432. Moya-Camarena SY, Heuvel JPV, Blanchard SG et al.: Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARα. J. Lipid Res. 40(8), 1426-1433 (1999).
433. LaRosa PC, Miner J. Xia Y et al.: Trans- 10, cis- 12 conjugated linoleic acid causes inflammation and delipidation of white adipose tissue in mice: a microarray and histological analysis. Physiol. Genomics 27(3), 282-294 (2006).
434. Kang K, Liu W, Albright KJ et al.: Trans-10, cis-12 CLA inhibits differentiation of 3T3-L1 adipocytes and decreases PPARγ expression. Biochem. Biophys. Res. Commun. 303(3), 795-799 (2003).
435. Roche HM, Noone E, Sewter C et al.: Isomer-dependent metabolic effects of conjugated linoleic acid: insights from molecular markers sterol regulatory element-binding protein-1c and LXRα. Diabetes 51(7), 2037-2044 (2002).
436. Adams SH, Lei C, Jodka CM et al.: PYY (3-36) administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J. Nutr. 136(1), 195-201 (2006).